Northern Trust Corp Myovant Sciences Ltd. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$24.03 - $27.02 $85,282 - $95,893	3,549 Added 3.59%	102,282 $2.76 Million
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $1,484 - $2,616	128 Added 0.13%	98,733 $1.77 Million
Q2 2022 Aug 12, 2022	BUY	$7.78 - $14.69 $54,670 - $103,226	7,027 Added 7.67%	98,605 $1.23 Million
Q1 2022 May 13, 2022	SELL	$11.38 - $16.4 $18,731 - $26,994	-1,646 Reduced 1.77%	91,578 $1.22 Million
Q4 2021 Feb 08, 2022	SELL	$14.31 - $23.87 $3,305 - $5,513	-231 Reduced 0.25%	93,224 $1.45 Million
Q3 2021 Nov 15, 2021	BUY	$18.94 - $26.99 $55,475 - $79,053	2,929 Added 3.24%	93,455 $2.1 Million
Q2 2021 Aug 13, 2021	BUY	$17.07 - $24.56 $15,226 - $21,907	892 Added 1.0%	90,526 $2.06 Million
Q1 2021 May 12, 2021	BUY	$20.46 - $25.18 $1.63 Million - $2 Million	79,471 Added 781.96%	89,634 $1.85 Million
Q4 2020 Feb 11, 2021	SELL	$13.8 - $27.62 $96 - $193	-7 Reduced 0.07%	10,163 $281,000
Q3 2020 Nov 16, 2020	BUY	$14.05 - $22.6 $168 - $271	12 Added 0.12%	10,170 $143,000
Q2 2020 Aug 14, 2020	SELL	$7.34 - $20.84 $924 - $2,625	-126 Reduced 1.23%	10,158 $209,000
Q1 2020 May 14, 2020	BUY	$6.55 - $14.76 $1,133 - $2,553	173 Added 1.71%	10,284 $78,000
Q4 2019 Feb 14, 2020	SELL	$4.2 - $19.21 $5,892 - $26,951	-1,403 Reduced 12.19%	10,111 $157,000
Q3 2019 Nov 13, 2019	SELL	$5.19 - $9.46 $5 - $9	-1 Reduced 0.01%	11,514 $59,000
Q2 2019 Aug 13, 2019	BUY	$8.69 - $25.0 $100,065 - $287,875	11,515 New	11,515 $105,000
Q4 2018 Feb 12, 2019	SELL	$15.01 - $25.2 $448,003 - $752,144	-29,847 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$19.33 - $26.78 $576,942 - $799,302	29,847 New	29,847 $792,000

Others Institutions Holding MYOV

# of Institutions

Shares Held

61.3K

Call Options Held

Put Options Held

View Full List

About Myovant Sciences Ltd.

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

More about MYOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account